New antibody aims to tame rare bleeding disorder

NCT ID NCT07623525

Recruiting now Disease control Sponsor: Diagonal Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 5 times

Summary

This early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with some participants receiving a placebo. It also includes a small group of HHT patients who have a related lung condition called pulmonary arterial hypertension.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DIAG723, an experimental antibody that targets two proteins to help repair blood vessels
What this could lead to: If successful, this could point toward a new treatment to reduce bleeding and other complications in people with HHT.
What could go wrong: This is a very early first-in-human study with only 93 participants, so safety and effectiveness are not yet known. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Altasciences Company
NOT_YET_RECRUITING

Laval, Quebec, H7V 4B3, Canada
BioPharma
NOT_YET_RECRUITING

Toronto, Ontario, M9L 3A2, Canada
Chris O'Brien Lifehouse
NOT_YET_RECRUITING

Camperdown, New South Wales, 2050, Australia
Doherty Clinical Trials
RECRUITING

East Melbourne, Victoria, 3002, Australia

Contact Email: •••••@•••••
New Zealand Clinical Research - Auckland
RECRUITING

Grafton, Auckland, 1010, New Zealand
Nucleus Network
NOT_YET_RECRUITING

Herston, Queensland, 4029, Australia
Perth Blood Institute
NOT_YET_RECRUITING

West Perth, Western Australia, 6005, Australia
Royal Brisbane and Women's Hospital
NOT_YET_RECRUITING

Herston, Queensland, 4029, Australia
Royal Melbourne Hospital
NOT_YET_RECRUITING

Parkville, Victoria, 3052, Australia
Royal Prince Alfred Hospital
NOT_YET_RECRUITING

Camperdown, New South Wales, 2050, Australia

Contact Email: •••••@•••••
Scientia Clinical Research Ltd
RECRUITING

Randwick, New South Wales, 2031, Australia

Contact Email: •••••@•••••
St. Michael's Hospital
NOT_YET_RECRUITING

Toronto, Ontario, M5B1W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.